This MedLibrary.org supplementary page on Zileuton is provided directly from the open source Wikipedia as a service to our readers. Please see the note below on authorship of this content, as well as the Wikipedia usage guidelines. To search for other content from our encyclopedia supplement, please use the form below:
Related Sponsors
 |
|
 |
|
|
Zileuton
|
|
| Systematic (IUPAC) name | |
| 1-(1-benzothiophen-2-ylethyl)-1-hydroxy-urea | |
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C11H12N2O2S |
| Mol. mass | 236.291 g/mol |
| Pharmacokinetic data | |
| Bioavailability | Not yet established |
| Protein binding | 93% |
| Metabolism | Hepatic (CYP1A2, CYP2C9 and CYP3A4-mediated) |
| Half life | 2.5 hours |
| Excretion | Renal |
| Therapeutic considerations | |
| Pregnancy cat. |
C(US) |
| Legal status | |
| Routes | Oral |
Zileuton (INN) is an asthma drug. It blocks leukotriene synthesis by inhibiting 5-lipoxygenase, an enzyme of the eicosanoid synthesis pathway. Zileuton was introduced in 1997 by Abbot Laboratories and is now marketed by Critical Therapeutics under the brand name ZYFLO. The original four-times-per-day immediate-release formulation of zileuton, known as ZYFLO IR, was, as of March 1st, 2008, discontinued and replaced by ZYFLO CR[1]
Contents |
Pharmacotherapy
Zileuton is indicated for the prophylaxis and chronic treatment of asthma in adults and children 12 years of age and older. Zileuton is not indicated for use in the reversal of bronchospasm in acute asthma attacks. Therapy with zileuton can be continued during acute exacerbations of asthma. The recommended dose of ZYFLO CR is two 600 mg extended-release tablets twice daily, within one hour after morning and evening meals, for a total daily dose of 2400 mg.
Related compounds include montelukast (Singulair) and zafirlukast (Accolate). These two compounds block the leukotriene receptor, while zileuton blocks the synthesis of leukotrienes.
Contraindications and Warnings
Zileuton frequently causes liver enzyme elevations and thus are contraindicated in patients with active liver disease or transaminase elevations greater than or equal to three times the upper limit of normal. Liver enzymes should be monitored prior to administering zileuton and repeated on a regular basis while patients are on the medication.
Zileuton is a potent inhibitor of CYP1A2[2][3] and thus has several clinically important drug interactions, such as inhibiting warfarin and theophylline metabolism. It lowered theophylline clearance significantly, doubling the AUC and prolonging half-life by nearly 25%. Because of theophylline's relation to caffeine (both being a methylxanthine, and theophylline being a metabolite of caffeine), caffeine's metabolism and clearance may also be reduced [4]. The R-isomer of warfarin metabolism and clearance is mainly affected by zileuton, while the S-isomer is not (because of metabolism via different enzymes). This can lead to an increase in prothrombin time [5].
See also
External links
References
- ^ Drug Shortages
- ^ Zyflo™ Filmtab® (zileuton) package insert. Chicago, IL: Abbott Laboratories; 1998 Mar.
- ^ Granneman GR, Braeckman RA, Locke CS, et al. Effect of zileuton on theophylline pharmacokinetics. Clin Pharmacokinet 1995;29:77—83.
- ^ Cafcit® (caffeine citrate) package insert. Evansville, IN: Mead Johnson & Company; 2003 May.
- ^ Zyflo™ Filmtab® (zileuton) package insert. Chicago, IL: Abbott Laboratories; 1998 Mar.
|
|||||||||||||||||||||||||||||||||||||
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
Wikipedia content modification information:
- This page was last modified on 7 October 2008, at 20:22.
Wikipedia Authorship and Review
Wikipedia content provided here is not reviewed directly by MedLibrary.org. Wikipedia content is authored by an open community of volunteers and is not produced by or in any way affiliated with MedLibrary.org.
Wikipedia Usage Guidelines
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article on "Zileuton".
The URL for this specific entry is:
All Wikipedia text is available under the terms of the GNU Free Documentation License. (See Copyrights for details). Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc.